OptiCell Solutions leverages extensive expertise in apheresis technology to deliver advanced apheresis treatments and cell collection solutions.
We aim optimize the field of apheresis by our innovative solution collecting target cells. This reduces the workload for the healthcare sector and accelerates their efforts making life-changing treatments available for patients. By offering high-quality cell collections, OptiCell Solutions provides the most crucial tool, “the starting material”, in a safe and secure manner. No matter what your research purpose or need for target cells may be, we can help you on your journey.
It all started with an interest in apheresis technology and the desire to help sick patients of all ages. Both nationally and internationally, there has been significant investment in the development of cell therapies, and the team has been working since 2019 to treat these patients with ATMPs (Advanced Therapy Medicinal Products) based on genes, tissues, and cells. They offer groundbreaking new opportunities for the treatment of disease and injury.
Jarmo Henriksson, a registered specialist nurse and founder of OptiCell Solutions AB, served as the head of the Apheresis unit at Karolinska University Hospital during its period of significant expansion. He possesses deep expertise in cell collection encompassing regulatory research ethics and has worked extensively with numerous industry stakeholders. The regional healthcare system was challenged to handle patient treatments and new cell collections, which necessitated substantial resource allocation to satisfy growing demands. It was during this time that Jarmo's vision for a private apheresis unit began to crystallize.
OptiCell Solutions was founded in 2024 by senior leaders with extensive experience from setting up new companies in the life science industry. The company was funded by private investors and CliniQnect AB, the later specialize in clinical trials. We aim to leverage the latest technology and our expertise of industry to streamline processes, enabling healthcare professionals to concentrate on what truly matters - patient care. By simplifying a complex process, we accelerate the healthcare sector’s transition to more efficient and patient-centered care.
The development of cell therapies continues to grow rapidly, and we want to be a part of this growth and feel that we are making a difference. Additionally, with our extensive experience in therapeutic apheresis treatments, we are well-equipped to support the healthcare sector should the need arise. Moving forward, we will deliver our services with expertise and dedicated commitment to making life-changing treatments available for patients.
We are addressing the challenges in cell therapy development by ensuring the highest quality and timely cell collections. We are eager to discuss your objectives and find the most effective ways to achieve them. Additionally, we are committed to pushing our boundaries to deliver even better results.
We can collaborate on every aspect of your project development, including planning, drafting project plans, managing projects, reporting, and handling regulatory matters. Every question is important, and together, we can achieve something extraordinary.
Contact our leadership for further discussions.
Membership in ATMP Sweden
Background / Challenges
Cell and Gene Therapy - challenges for the Biotech industry
Hundreds of trials are currently underway exploring cellular therapies derived from healthy donor immune cells. The content of starting material can mean the difference between a successful and an unsuccessful manufacturing run for a cell therapy product. It could even mean the difference between an effective and ineffective treatment for the patient. Without high-quality cell collection from high-quality donor, the success of advanced cellular therapies is not possible.
What's In The Leukopak Matters For Cell Therapy Manufacturing_October 11, 2024
Healthcare sector - challenges
The workload of the healthcare sector and their ability to make life-changing treatments available on time is constantly being questioned. The need for apheresis applications is constantly increasing, and in an aging population, the availability of other important treatment options is becoming more difficult to ensure that patients receive the most appropriate and equivalent care.
Information and support to patients when the waiting time cannot be fulfilled
Notice:
With leukapheresis, healthcare professionals can collect a 150 ml bag in a closed system that contains >20 times more target cells than a standard blood draw. The remaining blood is returned to the patient or cell donor. Leukapheresis is safe and as few and mild side effects. The team at OptiCell Solutions has extensive experience with leukapheresis, you and your cells can feel secure with us.
OptiCell Solutions AB
Via Hälsovägen 7, Elevator A, Floor 7
Via Blickagången 6A, Elevator A, Floor 7
141 57 Huddinge, Sweden
OptiCell Solutions
Novum Labs
Hälsovägen 7, Floor 5, Elevator E, Box 1
141 57 Huddinge, Sweden
Information
GCP - ICH guideline for good clinical practice
Audits from Medicines Agency, IVO, Biotech companies, Healthcare sector, The Pharmacy
Board of directors
Please visit www.allabolag.se
Annual Report
Please visit www.allabolag.se
IVO Register
Owners
CliniQnect AB, Jarmo Henriksson, Peter Rybäck, Patrik Åvestrand
Copyright © 2024 OptiCell Solutions AB. All rights reserved.